

# Regorafenib (Hydrochloride)

Catalog No: tcsc0725



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

835621-07-3

**Formula:**

$C_{21}H_{16}Cl_2F_4N_4O_3$

**Pathway:**

Protein Tyrosine Kinase/RTK;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK;Autophagy

**Target:**

VEGFR;Raf;PDGFR;Autophagy

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq$  5.6 mg/mL (10.78 mM)

**Alternative Names:**

BAY73-4506 hydrochloride

**Observed Molecular Weight:**

519.28


## Product Description

Regorafenib Hydrochloride is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with **IC<sub>50</sub>s** of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

IC50 & Target: IC50: 13 nM (VEGFR1), 4.2 nM (VEGFR2), 46 nM (VEGFR3), 22 nM (PDGFRβ), 7 nM (Kit), 1.5 nM (RET), 2.5 nM (Raf-1)

**In Vitro:** Regorafenib potently inhibits VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with an IC<sub>50</sub> of 3 nM. In HAoSMCs, regorafenib inhibits PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC<sub>50</sub> of 90 nM. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC<sub>50</sub> of 3 nM<sup>[1]</sup>. Regorafenib causes a concentration-dependent decrease in Hep3B cell growth, having an IC<sub>50</sub> of 5 μM. Regorafenib subsequently increases the levels of phospho-c-Jun, a JNK target, but not total c-Jun in Hep3B cells<sup>[3]</sup>.

**In Vivo:** Regorafenib effectively inhibits growth of the Colo-205 xenografts in the dose range of 10-100 mg/kg reaching a TGI of 75% at day 14 at the 10 mg/kg dose. In the MDA-MB-231 model, regorafenib is highly efficacious at a dose as low as 3 mg/kg, resulting in a significant TGI of 81%, which increases to 93% at doses of 10 and 30 mg/kg, where tumor stasis is reached<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!